Macrogen (038290) Fundamentals 2026 — P/E 31.5x, Revenue Analysis | SniperIQ
Macrogen (038290) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩120.2B, trading at ₩11090.00 on the KOE. This SniperIQ fundamentals page covers Macrogen's valuation (P/E 31.5x, P/B 0.8x), profitability (net margin 1.9%), revenue (₩195.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Macrogen's market cap?
Macrogen (038290) has a market capitalization of approximately ₩120.2B, trading at ₩11090.00 on the KOE. Market cap moves with the live share price.
What is Macrogen's P/E ratio?
Macrogen's trailing twelve-month P/E ratio is 31.5x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Macrogen?
Macrogen runs a net profit margin of 1.9%, a gross margin of 36.5%, and an operating margin of 1.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Macrogen generate?
Macrogen reported revenue of ₩195.3B for fiscal year 2025, with net income of ₩2.0B and earnings per share (EPS) of 187.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Macrogen pay a dividend?
Macrogen offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Macrogen financially healthy?
Macrogen carries a debt-to-equity ratio of 0.73x and a current ratio of 0.79x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Macrogen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Macrogen (038290) the key facts are: market cap ₩120.2B, P/E 31.5x, revenue ₩195.3B, 52-week range 10770-20900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Macrogen's full fundamentals live
Get Macrogen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.